New mRNA shingles vaccine shows promise in Mid-Stage trial

NCT ID NCT07285278

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new mRNA vaccine called ABO1108 to see if it can prevent shingles in adults aged 40 and above. About 300 healthy volunteers will receive two shots, two months apart, and be compared to a placebo group. The goal is to measure the immune response and check for safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ABO1108 (mRNA vaccine for shingles)

What this could lead to

If successful, this could lead to a new, more effective shingles vaccine for adults 40 and older.

What could go wrong

This is an early Phase 2 trial with only 300 people, so results may not apply to everyone. The vaccine may not work as well as hoped or could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VARICELLA-ZOSTER VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chickenpox varicella zoster infection herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rongshui Miao Autonomous County Center for Disease Control and Prevention

    Liuzhou, China